<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Atamyo Therapeutics Announces First Three Patients Dosed with ATA-200 Gene Therapy in on-going LGMD-R5 Clinical Trial, and Extension of Partnership with the Dion Foundation	</title>
	<atom:link href="https://atamyo.com/press-releases/atamyo-therapeutics-announces-first-three-patients-dosed-with-ata-200-gene-therapy-in-on-going-lgmd-r5-clinical-trial-and-extension-of-partnership-with-the-dion-foundation/feed/" rel="self" type="application/rss+xml" />
	<link>https://atamyo.com/press-releases/atamyo-therapeutics-announces-first-three-patients-dosed-with-ata-200-gene-therapy-in-on-going-lgmd-r5-clinical-trial-and-extension-of-partnership-with-the-dion-foundation/</link>
	<description>Changing life of Neuromuscular patients</description>
	<lastBuildDate>Tue, 03 Feb 2026 10:02:32 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.7.4</generator>
</channel>
</rss>
